Source: DGNews  |  Posted 9 years ago

By Charlene Laino

SAN ANTONIO, TX -- December 13, 2002 -- Serum human epidermal growth factor receptor 2 (HER-2/neu) is a useful marker for monitoring clinical response in patients on trastuzumab-based therapy, suggests a small retrospective analysis.

Walter Carney, PhD, Head of Oncogene Science at Bayer Corporation in Cambridge, Massachusetts, United States, spoke about the study here on December 12th on behalf of his colleagues at Bayer Corporation and Memorial Sloan-Kettering Cancer Center in New York, New York, United States, at the 25th Annual San Antonio Breast Cancer Symposium.

The study group comprised 37 patients who were tissue positive for HER-2/neu at diagnosis and treated with trastuzumab (Herceptin